WTA Implements Mandatory SRY Gene Testing to Meet 2028 Olympic Standards

Effective Tuesday, the WTA requires all professional players to undergo one-off SRY gene screening to ensure compliance with 2028 Los Angeles Olympic eligibility.

Effective Tuesday, the Women’s Tennis Association has instituted a one-off mandatory WTA gene testing protocol for every athlete competing on the professional circuit. This regulatory shift serves as a primary prerequisite for players seeking eligibility for the 2028 Los Angeles Olympics. The governing body updated its women’s eligibility policy this week to incorporate specific gender screening procedures rooted in biological sex markers. This administrative move follows a March eligibility directive issued by the International Olympic Committee (IOC), which corresponds with an executive order regarding sports participation signed by U.S. President Donald Trump in anticipation of the 2028 Games.

Under the newly ratified regulations, every professional player must undergo screening for the SRY gene, a DNA sequence typically found on the Y chromosome. This specific genetic marker is responsible for initiating male sex development during gestation and indicates the presence of testes. The WTA’s updated framework classifies a 'biological male' as any person possessing the SRY gene who currently has, or previously possessed, testes or streak testes. This definition remains independent of an individual’s legal sex or self-identified gender. Conversely, the organization defines a 'biological female' as a person lacking the SRY gene who has, or previously had, ovaries or streak ovaries.

By enforcing these screening measures, the WTA is adhering to a mandate from the IOC, a directive that various other Olympic sporting federations are currently adopting. The association maintains that these protocols are essential to protect the integrity of the women’s professional tour and ensure equitable competition environments for all entrants. While the policy is now officially active, the organization has not disclosed the number of transgender women currently competing at the elite level of the sport. The WTA clarified that the policy draws a sharp distinction between biological sex and gender identity, stating that the rules are not intended to diminish the dignity of any individual.

Tennis now joins a growing list of global sporting disciplines that have implemented mandatory gender verification protocols, including boxing, skiing, and track and field. The transition to mandatory genetic screening has drawn scrutiny from human rights advocates and activist organizations who question the necessity of such invasive measures. The policy change in Berlin represents a fundamental shift in the administrative obligations of professional female athletes, aligning the sport with the broader regulatory landscape established for the upcoming 2028 Los Angeles Olympics. This one-time testing mandate is now a permanent component of the tour’s eligibility criteria to ensure full compliance with international standards.

The implementation of these genetic tests marks the first time the WTA has required DNA-level verification for its entire roster of athletes. Players who fail to provide the necessary genetic documentation will be ineligible for sanctioned tournament play and Olympic qualification. The organization has established a timeline for current players to complete the screening, ensuring that all data is processed well before the 2028 qualification window opens. Medical professionals will oversee the collection of samples to maintain the chain of custody and ensure the accuracy of the SRY gene results. This data will be stored securely as part of the athlete’s permanent eligibility profile.

Furthermore, the WTA’s decision reflects a broader trend in international sports governance toward biological-based eligibility categories. The IOC’s March policy provided the framework for individual federations to define their own sex-based criteria, leading to the current WTA mandate. While the 2028 Games are several years away, the association is moving quickly to resolve any potential eligibility disputes. The focus remains on the SRY gene as the definitive biological marker for these purposes. This move ensures that the WTA remains in lockstep with the United States' domestic sports policies as the host nation for the next Summer Olympics. The association continues to emphasize that these measures are purely administrative and aimed at maintaining the historical structure of women’s professional tennis.